Silvercrest Asset Management Group LLC Has $4.18 Million Stock Holdings in Pfizer Inc. (NYSE:PFE)

Silvercrest Asset Management Group LLC decreased its position in shares of Pfizer Inc. (NYSE:PFE) by 76.5% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 157,640 shares of the biopharmaceutical company’s stock after selling 512,779 shares during the period. Silvercrest Asset Management Group LLC’s holdings in Pfizer were worth $4,182,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also made changes to their positions in the company. Rafferty Asset Management LLC lifted its stake in Pfizer by 11.4% in the 4th quarter. Rafferty Asset Management LLC now owns 656,744 shares of the biopharmaceutical company’s stock valued at $17,423,000 after purchasing an additional 67,007 shares during the last quarter. Raiffeisen Bank International AG bought a new position in Pfizer in the 4th quarter valued at approximately $1,027,000. Port Capital LLC lifted its stake in Pfizer by 23.6% in the 4th quarter. Port Capital LLC now owns 9,839 shares of the biopharmaceutical company’s stock valued at $261,000 after purchasing an additional 1,881 shares during the last quarter. ProShare Advisors LLC lifted its stake in Pfizer by 15.0% in the 4th quarter. ProShare Advisors LLC now owns 904,859 shares of the biopharmaceutical company’s stock valued at $24,006,000 after purchasing an additional 118,216 shares during the last quarter. Finally, Quantinno Capital Management LP lifted its stake in Pfizer by 6.6% in the 4th quarter. Quantinno Capital Management LP now owns 394,279 shares of the biopharmaceutical company’s stock valued at $10,460,000 after purchasing an additional 24,490 shares during the last quarter. Institutional investors and hedge funds own 68.36% of the company’s stock.

Analysts Set New Price Targets

PFE has been the subject of several research reports. Citigroup reissued a “neutral” rating on shares of Pfizer in a research note on Thursday, March 27th. Guggenheim reissued a “buy” rating on shares of Pfizer in a research note on Tuesday, March 18th. Cantor Fitzgerald initiated coverage on shares of Pfizer in a research note on Tuesday, April 22nd. They set a “neutral” rating and a $24.00 price target for the company. Hsbc Global Res raised shares of Pfizer to a “strong-buy” rating in a research note on Monday, March 10th. Finally, UBS Group raised their price target on shares of Pfizer from $24.00 to $25.00 and gave the company a “neutral” rating in a research note on Wednesday, April 30th. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating, four have given a buy rating and three have assigned a strong buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $29.17.

Pfizer Price Performance

Shares of NYSE PFE opened at $23.01 on Tuesday. Pfizer Inc. has a twelve month low of $20.92 and a twelve month high of $31.54. The firm has a fifty day simple moving average of $23.60 and a 200 day simple moving average of $25.28. The company has a market capitalization of $130.82 billion, a PE ratio of 16.32, a P/E/G ratio of 0.64 and a beta of 0.58. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share for the quarter, beating the consensus estimate of $0.67 by $0.25. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The firm had revenue of $13.72 billion during the quarter, compared to the consensus estimate of $14.43 billion. During the same period in the previous year, the firm posted $0.82 earnings per share. The business’s revenue was down 7.8% compared to the same quarter last year. On average, sell-side analysts forecast that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, June 13th. Shareholders of record on Friday, May 9th will be paid a $0.43 dividend. This represents a $1.72 annualized dividend and a yield of 7.48%. The ex-dividend date of this dividend is Friday, May 9th. Pfizer’s dividend payout ratio (DPR) is currently 124.64%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.